Treatment-Resistant Depression Clinical Trial
Official title:
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study will involve magnetic resonance scans to examine brain chemistry (neurotransmitter levels), brain activity, and functional connections between brain regions before and after participating in the trial. The neurotransmitters of interest are glutamate, glutamine, and GABA. Comparisons will be made between individuals who receive ziprasidone and individuals who receive an inactive placebo. Differences between participants who respond to standard antidepressants and those who require additional medication will also be examined. All participants will have a baseline magnetic resonance scan before starting medication. The second scan will be after 8 weeks of escitalopram treatment for those who respond or following 8 weeks of escitalopram plus ziaprasidone or placebo (16 weeks after starting) for those who do not respond to escitalopram alone. Participants will complete standard rating scales for depression at each visit.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02497287 -
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
|
Phase 3 | |
| Recruiting |
NCT03653858 -
Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression
|
N/A | |
| Recruiting |
NCT01868802 -
Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population
|
Phase 2 | |
| Recruiting |
NCT02462551 -
Focal Electrically Administered Seizure Therapy for the Treatment of Depression
|
N/A | |
| Recruiting |
NCT05377177 -
Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI
|
N/A | |
| Completed |
NCT05095792 -
Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
|
||
| Recruiting |
NCT06372834 -
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
|
N/A | |
| Active, not recruiting |
NCT03701724 -
Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression
|
N/A | |
| Recruiting |
NCT05800860 -
A Trial of GH001 in Patients With Treatment-resistant Depression
|
Phase 2 | |
| Not yet recruiting |
NCT06404320 -
Physical Activity Program for TRD
|
N/A | |
| Completed |
NCT01945047 -
Action of Ketamine in Treatment-Resistant Depression
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05045378 -
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
|
Phase 4 | |
| Completed |
NCT05454410 -
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
|
Phase 2 | |
| Recruiting |
NCT05422417 -
Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression
|
N/A | |
| Recruiting |
NCT05842291 -
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
|
N/A | |
| Recruiting |
NCT04821271 -
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
|
Phase 2 | |
| Active, not recruiting |
NCT04670081 -
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
|
Phase 2 | |
| Recruiting |
NCT05710237 -
Does Psilocybin Require Psychedelic Effects to Treat Depression?
|
Phase 2 | |
| Completed |
NCT03329391 -
Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression
|
N/A | |
| Not yet recruiting |
NCT05661383 -
Olfactory and Brain Stimulations in Treatment-resistant Depression
|
N/A |